Post has attachment
The global high-resolution melting analysis market is expected to reach USD 302.1 Million by 2021 from USD 259.4 Million in 2016, at a CAGR of 3.1% during the forecast period of 2016 to 2021.

This report provides an overall understanding of the global high-resolution melting analysis market. This report segments the market on the basis of product & service, application, end user, and region. On the basis of product and service, the global market is divided into instruments, reagents & consumables, and software & services. Among these products, the reagents and consumables segment accounted for the largest share of the market in 2016.

On the basis of application, the market is segmented into SNP genotyping, mutation discovery, species identification, pathogen identification, epigenetics, and other applications (HLA compatibility typing, zygosity testing, DNA fingerprinting, DNA mapping, association (case/control) studies, allelic prevalence in a population, and identification of candidate predisposition genes). In 2016, the SNP genotyping segment accounted for the largest share of the market.

On the basis of end user, the market is segmented into research laboratories & academic institutes, hospitals & diagnostics centers, pharmaceutical & biotechnology companies, and other end users. In 2016, the research laboratories & academic institutes segment accounted for the largest share of the global market.

In 2016, the North American region accounted for the largest share of the global high-resolution melting analysis market, followed by Europe. The rising prevalence of infectious diseases, genetic disorders & other chronic diseases, and the large number of genotyping-based research and development projects in this region are the key growth drivers for the North American market. Asia-Pacific is expected to witness the highest growth during the forecast period, due to its large patient population, improving healthcare infrastructure, growing per capita income, expansion of key market players, and increasing awareness of personalized medicine.

Market growth is propelled by the benefits of this technology, such as its high efficacy, significant accuracy, and small cycle times. Additionally, market growth is likely to be driven by the rising prevalence of infectious diseases & genetic disorders, increasing public-private investments in the genomics sector, funds & grants, rapid growth in the aging population, and improving healthcare infrastructure in emerging countries.

A combination of bottom-up and top-down approaches was used to calculate the market sizes and growth rates of the high-resolution melting analysis market and its subsegments. All percentage shares, splits, and breakdowns were determined using secondary sources and verified through primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. Primary interviews with key opinion leaders were also used to determine the percentage shares of each subsegment and the relative differences in growth rates.

The major players in the global market include Thermo Fisher Scientific Inc. (U.S.), F. Hofmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories (U.S.), and QIAGEN N.V. (Netherlands). Other players in the market include Agilent Technologies Inc. (U.S.), bioMérieux S.A. (France), Illumina, Inc. (U.S.), Meridian Bioscience, Inc. (U.S.), Novacyt (France), Azura Genomics (U.S.), Canon Biomedical (U.S.), and PREMIER Biosoft (U.S.), among others.

For more Information Visit : http://www.marketsandmarkets.com/Market-Reports/high-resolution-melting-analysis-market-216456020.html

Cell Therapy Segment Accounted for the Largest Share of the "Regenerative Medicines Therapy Market"

Download PDF Brochure @ http://bit.ly/2jbnMGR

The global regenerative medicines market is expected to reach USD 49.41 Billion by 2021 from USD 17.06 Billion in 2016, at a CAGR of 23.7%. The global market is broadly classified by product, application, therapy, and region.
On the basis of product, market is segmented into cell-based and acellular products. The cell-based products segment is further segmented into allogeneic and autologous products. Cell-based product segment is expected to account for the largest share of the global market in 2016 owing to the increasing demand of cell-based products, rapid rise in FDA approvals in the U.S., increasing organ transplantations, and increasing government initiatives.
On the basis of application, the regenerative medicines market is segmented into orthopaedic & musculoskeletal spine, dermatology, CNS, cardiovascular, oncology, diabetes, and others. The orthopaedic & musculoskeletal spine segment is expected to account for the largest share of this market because of the increasing number of FDA approvals in orthopaedic and increasing focus on research on musculoskeletal spine.

The prominent players in the market include Celgene Corporation (U.S.), Acelity (U.S.), StemCells, Inc. (U.S.), Organogenesis Inc. (U.S.), NuVasive, Inc. (U.S.), Vericel Corporation (Genzyme) (U.S.), Japan Tissue Engineering Co., Ltd. (Japan), among others.

Regenerative Medicines Market, By Product
Cell-based Products
Allogeneic
Autologous
Scaffold Free

Regenerative Medicines Market, By Therapy
Cell Therapy
Gene Therapy
Immunotherapy
Tissue Engineering

Post has attachment
Wait while more posts are being loaded